Aurinia Pharmaceuticals (AUPH) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Aurinia Pharmaceuticals Inc. presented new data at ASN Kidney Week 2024, highlighting the effectiveness of LUPKYNIS in treating lupus nephritis, particularly in diverse populations most affected by the disease. Real-world data showcased LUPKYNIS’s positive impact on kidney health compared to older therapies, with studies indicating improved outcomes and stronger podocyte stability at lower doses.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
